SKIN · SkinHealth Systems Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SKIN
this stock
SkinHealth Systems Inc.
|
$91.10M | -49.6% | -10.0% | — | 5.5% |
|
PG
PROCTER & GAMBLE Co
|
$337.67B | +1.4% | +3.3% | 21.9 | 1.2% |
|
UL
Unilever PLC
|
$133.55B | -5.2% | — | — | 0.2% |
|
CL
Colgate Palmolive Co
|
$69.19B | +9.8% | +1.7% | 34.3 | 2.2% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$43.33B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SKIN | +0.4% | +6.1% | -38.1% | +3.5% | -49.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +1.6% | +7.8% | -55.9% | +3.9% | -61.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.